“HPV vaccines allow the opportunity to enlist the woman’s own immune system to develop neutralising antibodies but studies indicate that current vaccines will only be effective if administered before exposure.
“These vaccines have shown no therapeutic efficacy for pre-existing infections,” he said.
Trials of both commercially-available vaccines, while demonstrating nearly 100 per cent efficacy in HPV-naďve populations, have shown diminished efficacy in populations due to exposure prior to vaccination.
Dr Wain said excessive promotion of these vaccines for use in women in the 24 to 45 year age group potentially diverts attention away from established methods of cervical cancer prevention based on cervical cytology.
“In the older age group, the vaccine is likely to be of substantially reduced efficacy because of either previous exposure or reduced risk of future exposure,” he said.
The
Medical Journal of Australia is a publication of the Australian Medical Association.
Source-MJA
SRM/ga